

National Cancer Institute
Institutional Review Board

AGENDA

February 23, 2015

1:00 – 5:00 pm

10 CRC/3-1608

- 1. Review of Draft Minutes, February 9, 2015**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
- 5. Problem Report Forms**
- 6. Other Expedited Actions**
- 7. Continuing Reviews**
- 8. Response to Stips** 11C0112-E, "Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer" - Tim Greten, PI
- 9. Amendment** 14C0131-B, "A Phase II, Open-label Study in Patients with BRAF V600E-Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib" - Robert Kreitman, PI
- 10. Amendment** 10C0174-M, "Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency" - Dennis Hickstein, PI
- 11. Amendment** 06C0014-J, "Prospective Evaluation of Epigenetic Alterations in Patients with Thoracic Malignancies" - David Schrupp, PI
- 12. Amendment** 12C0151-F, "Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum" - David Schrupp, PI